FDA Accepts BLA for Ivonescimab in NSCLC, Sets November 2026 PDUFA Date

summarizeSummary

The FDA has accepted Summit Therapeutics' Biologics License Application for ivonescimab in EGFR-mutated NSCLC and set a PDUFA goal action date of November 14, 2026.

check_boxKey Events

• FDA Accepts BLA for Ivonescimab

  The U.S. Food & Drug Administration (FDA) has accepted for filing Summit Therapeutics' Biologics License Application (BLA) for ivonescimab.

• PDUFA Goal Date Set

  The FDA has provided a Prescription Drug User Fee Act (PDUFA) goal action date of November 14, 2026, for a decision on the application.

• Application Based on HARMONi Study

  The BLA seeks approval for ivonescimab in combination with chemotherapy for EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) post-tyrosine kinase inhibitor (TKI) therapy, based on results from the Phase III HARMONi trial.

auto_awesomeAnalysis

Summit Therapeutics announced that the FDA has accepted its Biologics License Application (BLA) for ivonescimab, a significant regulatory milestone following the BLA submission on January 12, 2026. The acceptance confirms the FDA has deemed the application complete and ready for substantive review. The assigned PDUFA goal action date of November 14, 2026, provides a clear timeline for a potential approval decision, which is crucial for investors tracking the commercialization prospects of this key oncology asset. This development de-risks the regulatory pathway for ivonescimab in EGFR-mutated non-small cell lung cancer, a market with substantial unmet need.